Iveda Solutions (IVDA) reprices 100K director options at $0.29

Rhea-AI Filing Summary

Iveda Solutions director Robert Gillen reported offsetting option transactions tied to an option repricing. He was granted 100,000 stock options on an "acquire" transaction and disposed of 100,000 options back to the issuer on a separate "disposition to issuer" transaction, leaving 128,599 options reported as held afterward.

According to a board-approved repricing on February 23, 2026, his options were reset to an exercise price of $0.29 per share while all other terms remained unchanged. The company states these transactions were exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gillen Robert

(Last) (First) (Middle)

1744 S. VAL VISTA DRIVE,

STE. 213

(Street)

MESA AZ 85204

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Iveda Solutions, Inc. [ IVDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$0.82	12/29/2025		D		100,000		12/29/2025	12/29/2035	Common Stock	100,000	$0.00	128,599	D
Options (Right to Buy)	$0.29(1)	02/23/2026		A		100,000		12/29/2025	12/29/2035	Common Stock	100,000	$0.00	128,599	D

Explanation of Responses:

1. On February 23, 2026, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $0.29 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

	/s/ Robert D. Gillen	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Iveda Solutions (IVDA) disclose for Robert Gillen?

Iveda Solutions disclosed that director Robert Gillen reported two derivative transactions in stock options: a grant of 100,000 options classified as an acquisition and a disposition of 100,000 options back to the issuer, both reflected as options with rights to buy company shares.

How many Iveda (IVDA) stock options were involved in Robert Gillen’s Form 4 filing?

The Form 4 shows 100,000 stock options acquired and 100,000 options disposed of, each priced at $0.00 in the transaction records. After these transactions, Gillen’s reported holdings in options stood at 128,599, according to the totals listed following the transactions.

Did the Iveda (IVDA) Form 4 change Robert Gillen’s total option holdings?

The filing lists 128,599 options reported as held following each transaction, suggesting the grant and disposition were structured so the reported total remained the same. The activity reflects an internal adjustment rather than a net increase or decrease in his option position.

What exercise price was set in Iveda (IVDA) director Robert Gillen’s option repricing?

The board-approved repricing reset Robert Gillen’s stock options to an exercise price of $0.29 per share. The company notes that all other terms of the options remained unchanged, indicating only the strike price was modified as part of this repricing.

Were Iveda (IVDA) director Robert Gillen’s option repricing transactions exempt under SEC rules?

Yes. The footnote explains that Gillen’s option repricing transactions were exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act. These rules can provide exemptions for certain insider transactions approved under specified conditions, such as board-authorized equity compensation changes.

What type of securities did Robert Gillen transact in at Iveda Solutions (IVDA)?

The transactions involved derivative securities described as "Options (Right to Buy)." These options give the holder the right to purchase Iveda Solutions shares at a set exercise price, which after the board’s repricing was adjusted to $0.29 per share while other terms stayed the same.